Loading organizations...
PHC Global, operating as The Public Health Company, develops and deploys advanced technology to deliver critical biothreat intelligence. The company’s core product involves systems designed to deter and detect natural, accidental, deliberate, and novel biological agents. It leverages proprietary and open-source data, data science, and sophisticated technologies to provide strategic and operational intelligence, thereby enhancing biosecurity measures.
Dr. Charity Dean founded PHC Global in 2020, following insights gained during the COVID-19 pandemic. Her experience highlighted significant vulnerabilities and intelligence gaps in national biodefense capabilities, revealing a pressing need for a more robust system against future pathogenic threats. This understanding spurred the creation of the company, aiming to fundamentally reimagine and strengthen global biodefense.
The company's intelligence solutions currently serve entities such as the Defense Innovation Unit at U.S. military installations worldwide, protecting personnel and vital assets. PHC Global's long-term vision is to lead the development of a comprehensive global biodefense system, positioning the U.S. and its allies to effectively deter and counter the full spectrum of biothreats and secure a lasting advantage in biosecurity.
The Public Health Company has raised $8.0M across 1 funding round.
The Public Health Company has raised $8.0M in total across 1 funding round.
The Public Health Company has raised $8.0M across 1 funding round. Most recently, it raised $8.0M Seed in April 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2021 | $8M Seed | — | Dragoneer Investment Group, Greylock, IVP, Tenaya Capital, Venrock, Howard Schultz, Paul George, Sweat Equity Ventures, Verily | Announced |
The Public Health Company has raised $8.0M in total across 1 funding round.
The Public Health Company's investors include Dragoneer Investment Group, Greylock, IVP, Tenaya Capital, Venrock, Howard Schultz, Paul George, Sweat Equity Ventures, Verily.
# The Public Health Company: High-Level Overview
The Public Health Company (PHC) is a technology platform that helps businesses, healthcare providers, and public health systems prevent, detect, and contain infectious disease outbreaks.[1] Founded in 2020 and officially launched in April 2021, PHC has developed the first Public Health as a Service (PHaaS) platform—a software solution that combines real-time public health data, containment best practices, and genomic epidemiology to give organizations actionable recommendations for managing disease risk while maintaining operational continuity.[1][2]
The company addresses a critical gap in how organizations approach infectious disease management. Rather than reacting to outbreaks after they occur, PHC enables a proactive risk management approach by systematizing the integration of epidemiological expertise with operational decision-making.[1] This is particularly valuable for enterprises that must balance employee and customer safety with business continuity—a challenge that became acute during the COVID-19 pandemic but remains relevant for ongoing threats like avian influenza and emerging pathogens.
# Origin Story
PHC was founded by Dr. Charity Dean, a public health expert and CEO, alongside co-founders with backgrounds in public health, technology, and infectious disease expertise.[1] The company emerged directly from the lessons of the COVID-19 pandemic, which exposed how unprepared most organizations were to manage communicable disease risk systematically. Rather than treating disease outbreaks as purely public health matters, PHC recognized that businesses needed a dedicated platform to translate epidemiological intelligence into operational guidance.
The company achieved early validation through a $8 million seed funding round closed at launch, backed by prominent investors including Venrock, Verily (Google's life sciences division), and Sweat Equity Ventures.[1] This funding reflected investor confidence in both the founding team's expertise and the market need for such a platform. As of the most recent data, PHC operates with approximately 183 employees and maintains headquarters in Goleta, California.[2]
# Core Differentiators
# Role in the Broader Tech Landscape
PHC operates at the intersection of several powerful trends: the normalization of biosecurity as a business risk, the digitization of public health infrastructure, and the growing recognition that infectious disease threats are ongoing rather than episodic. The COVID-19 pandemic permanently shifted how enterprises view communicable disease from a peripheral concern to a material operational risk.
The company's timing is particularly significant because it arrives as organizations are moving beyond pandemic-era ad hoc responses toward systematic, data-driven disease risk management. PHC's platform approach—treating disease surveillance and response as a continuous, technology-enabled process rather than a crisis response—aligns with broader enterprise trends toward predictive analytics and operational resilience.
By creating a bridge between public health expertise and business operations, PHC influences how organizations think about biosecurity. It legitimizes disease risk management as a standard operational function rather than an emergency measure, potentially reshaping how enterprises budget for and prioritize health-related operational resilience.
# Quick Take & Future Outlook
PHC is positioned to become a critical infrastructure layer for enterprise biosecurity as organizations increasingly recognize that infectious disease risk is structural and ongoing. The company's success will likely depend on expanding its data integrations, deepening its genomic epidemiology capabilities, and demonstrating measurable impact on outbreak prevention and containment costs.
The broader trajectory suggests growing demand for such platforms as novel pathogens emerge and organizations seek to avoid the operational disruptions of the COVID-19 era. PHC's ability to serve as a trusted intelligence provider across businesses, healthcare systems, and public health agencies could position it as a central node in a more resilient, data-driven approach to communicable disease management—transforming what was once purely a public health function into a core enterprise operational capability.
